Program Plus Tablets for Tiny Dogs 1 - 4.5kg (pack of 6)

Milbemycin  belongs to the group of macrocyclic lactones, isolated from the fermentation of Streptomyces hygroscopicus var. aureolacrimosus. Out of the selected analogues, the one currently used for medicinal purposes is Milbemycin A3/A4 oxime (ratio ≤20 : ≥80). As one of the active principles in Program Plus, it is effective against larval stages (L3, L4, and the microfilariae) of Dirofilaria immitis, and anthelmintic activity against the following nematodes: Toxocara canis, Trichuris vulpis, Ancylostoma caninum. The activity of milbemycin is correlated with its action on invertebrate neurotransmission: it potentiates GABA (gamma-amino-butyric acid), an inhibitor of neuromuscular transmission, leading to paralysis.

Lufenuron  belongs to the chemical group of benzoylureas, and is considered an IGR (Insect Growth Regulator) or IDI (Insect Development Inhibitor). It inhibits the development of fleas by interfering with the normal synthesis, polymerisation and deposition of the chitin, the principal component of the arthropod exoskeleton. The adult flea absorbs lufenuron via its bloodmeal. At therapeutic levels, lufenuron has no effect upon adult fleas, but passes transovarially to act upon certain stages of the development of the insect (egg and larva), thus interrupting the insect life cycle. Also, adult flea faeces containing lufenuron exert a larvicidal effect when ingested by the larvae directly.

Active substances

Milbemycin oxime 2.3 mg

Lufenuron 46.0 mg

Excipient:

Titanium dioxide (E171) 0.7 mg

Program Plus is a prescription product and must be applied according to the instructions of your veterinary surgeon.
Please read the product leaflet thoroughly before applying to your pet.

Marketing Authorisation Holder
Elanco Europe Ltd
Lilly House
Priestley Road
Basingstoke
Hampshire
RG24 9NL
UNITED KINGDOM

Marketing Authorisation Number
Vm 00879/4029

Contraindications
Do not use in case of hypersensitivity to the active substance, to the adjuvants or to any of the excipients.

Special warnings
Ideally, tablets are administered on the same day each month. If an interval is greater than 6 weeks, treatment should be resumed immediately and be continued at monthly intervals and, in case of heartworm prevention, a veterinarian should be consulted.

Special precautions for use in animals
In heartworm risk regions, or in case it is known that a dog has been travelling to and from heartworm risk regions, before commencing PROGRAM Plus treatment as with any other heartworm preventive, a veterinary consultation is advised to exclude the presence of any concurrent infestation of Dirofilaria immitis. In the case of a positive diagnosis, adulticidal therapy is indicated before administering PROGRAM Plus.

Special precautions to be taken by the person administering the veterinary medicinal product to animals
None.
In the case of accidental ingestion seek medical advice immediately and show the package leaflet or the label to the physician.

Adverse reactions (frequency and seriousness)
Pale mucous membranes, increased intestinal peristalsis, lethargy, diarrhea have been observed very rarely after treatment. The treatment of dogs with a high number of circulating microfilariae can sometimes lead to the appearance of moderate and transitory hypersensitivity reactions, such as pale
mucous membranes, vomiting, laboured breathing, or excessive salivation. These reactions are associated with the release of proteins from dead or dying microfilariae and are not a direct toxic effect of the product.

Use during pregnancy, lactation or lay
Pregnancy:
Can be used during pregnancy.
Lactation:
Can be used during lactation.

Interaction with other medicinal products and other forms of interaction
During treatment with PROGRAM Plus, no other antiparasitic macrocyclic lactones should be administered.